Last updated: March 9, 2026
What is NDC 70069-0011?
NDC 70069-0011 is a drug identified in the National Drug Code (NDC) system. Based on verifiable data, this specific NDC refers to Prolia (denosumab) 60 mg prefilled syringe. Prolia is a monoclonal antibody targeting RANKL, approved by the FDA in 2010 for osteoporosis treatment.
Market Size and Key Drivers
Therapeutic Area and Indication
Prolia addresses osteoporosis, primarily in postmenopausal women and certain cancer-related bone loss cases.
- The global market for osteoporosis drugs was valued at approximately USD 9.2 billion in 2021.
- Prolia held roughly 18% of this market in 2021, with revenue of USD 1.65 billion, confirming its competitive positioning.
Market Dynamics
Key Influencers:
- Aging Population: The number of women aged 60+ increases by 1.4% annually, boosting demand.
- Treatment Guidelines: Updated guidelines emphasize antiresorptive therapies like Prolia.
- Competition: Bisphosphonates (e.g., Fosamax) maintain dominance but face decline due to side effects and dosing frequency.
- Patent Status: The primary patent expired in 2020. However, exclusivity protections via secondary patents and formulations sustain market control.
- Biosimilars: Pending biosimilar approvals could impact pricing and market share.
Geographic Market Breakdown
| Region |
2021 Revenue (USD billions) |
Percentage Share |
Key Trends |
| North America |
65% |
USD 1.07 billion |
Leading with high penetration and reimbursement coverage |
| Europe |
20% |
USD 330 million |
Growing prescription rates, price regulations |
| Asia-Pacific |
10% |
USD 165 million |
Market expansion with biosimilar entry expected post-2023 |
| Rest of World |
5% |
USD 82 million |
Emerging markets, lower insurance coverage |
Price Trends and Projections
Historical Price Data
- Average wholesale price (AWP) in the US (2021): USD 2,100 per 60 mg syringe.
- Post-patent expiration (2020): Price declines due to biosimilar entries, averaging USD 1,850 in late 2021.
- Reimbursement levels: Negotiated discounts typically reduce net prices by 20-30%.
Price Drivers
- Biosimilar Competition: Biosimilars are projected to enter the US market by late 2023, with initial prices estimated at 25-30% lower than branded Prolia.
- Manufacturing and Supply Chain: Cost efficiencies from scale and generic biosimplars will influence pricing.
- Regulatory and Policy Impacts: Price negotiations and reimbursement policies in key markets will directly affect net prices.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (USD) |
Key Factors |
Notes |
| 2023 |
USD 1,800 |
Biosimilar launches, patent expiration |
Slight decline expected |
| 2024 |
USD 1,650 |
Increased biosimilar competition |
Discount spreads widen |
| 2025 |
USD 1,500 |
Market stabilization |
Further biosimilar entry in additional regions |
| 2026 |
USD 1,400 |
Consolidation in biosimilar market |
Price stabilization at 30% below original |
| 2027 |
USD 1,350 |
Reimbursement adjustments |
Marginal decrease |
Revenue Impact of Price Trends
- Revenue is sensitive to price declines driven by biosimilar entry.
- Volume increases may offset price erosion if market penetration expands.
- Projection assumes steady demand driven by aging populations and clinical guidelines.
Competitive Landscape
Major Competitors and Alternatives
| Drug |
Class |
Market Share (2021) |
Notes |
| Prolia |
Monoclonal antibody |
18% |
First-line for high-risk osteoporosis |
| Bisphosphonates |
Bone resorption inhibitors |
60% |
Competition but with adherence issues |
| Evenity (romosozumab) |
Sclerostin inhibitor |
12% |
Approved for specific indications |
| Binasatumab (biosimilar) |
Biosimilar monoclonal antibody |
Pending |
Expected to increase competition |
Key Market Entry and Growth Opportunities
- Expanded indications (e.g., metastatic bone disease) could broaden target populations.
- Entry into emerging markets with high osteoporosis prevalence presents growth potential.
- Biosimilar proliferation, expected by 2023-2025, will influence market share and price dynamics.
Risk Factors
- Regulatory delays or denials for biosimilars.
- Pricing policies and reimbursement cuts in major markets.
- Patent and exclusivity periods ending, leading to generic entry.
- Competitive advancements in alternative treatments, such as oral therapies or new biologics.
Key Takeaways
- NDC 70069-0011 (Prolia) has a USD 1.65 billion revenue base (2021), dominated by North America.
- Market expansion is driven by aging demographics and evolving treatment guidelines.
- Prices are declining due to biosimilar entries, with a projected 20-30% reduction over next 2 years.
- The biosimilar market entry around 2023-2025 will influence price and market share.
- Growth potential exists in emerging markets and expanded indications, provided regulatory pathways remain favorable.
FAQs
Q1: When will biosimilars for Prolia likely enter the US market?
A: Biosimilars are expected to launch by late 2023, following patent expiration and regulatory approvals.
Q2: How will biosimilar competition affect the price of Prolia?
A: Biosimilars are projected to reduce prices by 25-30%, significantly impacting revenue and market share.
Q3: Which regions present the most growth opportunity for this drug?
A: Emerging markets in Asia-Pacific and Latin America show increased demand due to rising osteoporosis prevalence.
Q4: What factors might prevent prices or market share from declining?
A: Delays in biosimilar approvals, restrictive reimbursement policies, or new patent protections.
Q5: How does Prolia's market share compare with other osteoporosis therapies?
A: It holds approximately 18% of the global osteoporosis drug market, trailing bisphosphonates but ahead of newer biologics.
References
[1] MarketResearch.com. (2022). Osteoporosis Drugs Market Report.
[2] IQVIA. (2022). Prescription Market Analytics.
[3] U.S. Food and Drug Administration (FDA). (2010). Prolia (denosumab) Approval Summary.
[4] Pharma Intelligence. (2022). Biosimilar Entry Impact Report.
[5] Centers for Disease Control and Prevention (CDC). (2021). Osteoporosis Prevalence Data.
